Recent news on Xolair

Breakthrough asthma drug  -  May 23, 2007
NorthJersey.com,That is, until 10 months ago, when Micah started taking what experts say is a breakthrough drug for treating allergy-induced asthma: Xolair.

Breakthrough drug available to treat allergy-induced asthma  -  May 22, 2007
Wilkes Barre Times-Leader,Micah McKitric of Lexington, Ky., who has severe allergic asthma, said that since he’s been on a new drug called Xolair, he is no longer afraid to go

New drug shows promise of relief from allergic asthma  -  May 21, 2007
Macon Telegraph,Xolair is a legitimate breakthrough drug for treating allergy-induced asthma, according to Mike Tringle, director of external affairs for the Asthma and

Tanox Reports 2007 First Quarter Results  -  May 10, 2007
PharmaLive.com (press release),Net royalty revenue from sales of Xolair(R) (omalizumab) was $11.0 million for the first quarter of 2007, compared to net Xolair royalty revenue of $8.8

Asthma’s Breath of Hope?  -  Apr 22, 2007
Red Herring,While not an immunological therapy, Genentech’s Xolair is perhaps the only asthma treatment on the market that is developed from biotechnology methods,

Asthma Medication Could Stop You Cold  -  Apr 21, 2007
Lawyers and Settlements,Washington, DC: Americans suffering from asthma may be worse off after taking the drug XOLAIR, according to a recent warning by the United States Food and

Relief in sight as asthma mum set to get treatment  -  Apr 12, 2007
Advertiser 24,...who has been waiting for 16 months for treatment with the injection Xolair at the Royal Brompton Hospital in London where she is a patient.

Genentech Q1 Profit, Revenue Top Consensus; Sees FY07 EPS Growth ...  -  Apr 11, 2007
Trading Markets,Genentech's asthma drug Xolair ringed in sales of $111 million in the first quarter, compared to $95 million in the same period prior year.

Genentech Q1 2007 Earnings Call Transcript  -  Apr 11, 2007
Seeking Alpha,US sales for Xolair were $111 million in Q1, a 17% increase compared to the same quarter last year. Penetration in our target market of moderate to severe

Vioxx Casts A Long, Long Shadow  -  Apr 17, 2007
BusinessWeekIn February regulators asked Genentech Inc. (DNA ) to relabel its allergy-related asthma drug Xolair, which had $425 million in sales last year,

Despite FDA Black Box Warning and Restriction to Second-Line Use ...  -  Mar 29, 2007
Drug Newswire (press release),The report also finds that 20% of eligible adult asthma patients fail to receive Genentech/Novartis's Xolair because of managed care organizations'

Drug Jitters  -  Apr 2, 2007
BusinessWeekThe sleeping-pill announcement followed on the heels of a February request by the FDA that Genentech (DNA) relabel its allergy-related asthma drug Xolair,

Genentech earnings soar but Lucentis sales slow down slightly  -  Apr 12, 2007
Pharma Times (subscription),The arthritis and non-Hodgkin's lymphoma drug Rituxan (rituximab) posted a 12% gain to $535 million, while Xolair (omalizumab) for severe asthma was up 17%

Aerovance Tops Off Series C By Garnering $32M Payout  -  Mar 27, 2007
BioWorld Online,And while asthma drug Xolair (omalizumab, Genentech Inc. and Novartis AG) inhibits IgE and must be injected, Aerovant inhibits upstream targets IL-4 and

Novartis Q1 beats forecasts on across-the-board growth; confirms ...  -  Apr 22, 2007
Hemscott,Rapid growth also came from Femara, Xolair, Exjade, Lucentis and Prexige. The first quarter performance also included four important new regulatory

Genentech Announces First Quarter 2007 Results  -  Apr 11, 2007
Genetic Engineering News (press release),LUCENTIS(R) 211 -- -- --------------------------------------- --------- --------- ---------- Xolair(R) 111 95 17

Despite FDA Black Box Warning and Restriction to Second-Line Use ...  -  27 Mar 2007
PR Newswire (press release),The report also finds that 20% of eligible adult asthma patients fail to receive Genentech/Novartis's Xolair because of managed care organizations'

FDA Proposes To Strengthen Label Warning For Xolair  -  Feb 26, 2007
Medical News Today (press release),The boxed warning emphasizes that Xolair, used to treat patients with asthma related to allergies, may cause anaphylaxis. Anaphylaxis may include trouble

Asthma UK Statement On Xolair  -  Feb 26, 2007
Medical News Today (press release),...'Xolair was passed as safe and effective by the European Medicines Agency (EMeA) in 2005 which means it is licensed for use across Europe and it is only

New hitch for asthma woman  -  Mar 22, 2007
Herts 24,Mother-of-six Mrs Hicks, aged 51, of Bluett Road, London Colney, has been waiting for 16 months for treatment with the injection Xolair at the Royal

Tanox Reports Fourth Quarter and Full Year 2006 Results  -  Mar 15, 2007
PR Newswire (press release),Net royalty revenue from sales of Xolair(R) (omalizumab) was $11.3 million for the fourth quarter of 2006, compared to net Xolair royalty revenue of $8.5

Taiwanese scientist wins illustrious award  -  Mar 20, 2007
Radio Taiwan International,...a condition that got him started on his research. After several years, he developed Xolair, a drug that minimizes the suffering associated with asthma.

Pharma Sector: Few Newsmakers Of The Week - Basilea Glaxo ...  -  Feb 25, 2007
Trading Markets,Genentech's asthma drug Xolair, which had to trudge a bumpy road before being approved in June 2003, is now hit with another snag. Xolair - administered as

Tanox posts second consecutive positive quarter  -  Mar 16, 2007
Houston Business Journal,The company attributed the increase in revenue to higher royalties from the asthma drug Xolair, as well as profit-sharing and revenue from manufacturing

Tanox Q4 Profit Plummets More Than 50% On Lower Revenues - Update  -  Mar 15, 2007
Trading Markets,The deal is expected to boost the development of the drug Xolair a treatment for allergic asthma. Genentech and Tanox have been working together in

Asthma mum to get vital new treatment  -  Mar 8, 2007
Advertiser 24,Carol Hicks, aged 51, of Bluett Road, London Colney, has been waiting for the past 15 months for treatment with the injection Xolair.

FDA will require stronger alerts for asthma drug  -  Feb 26, 2007
Jackson Clarion Ledger,Anaphylaxis can occur even if a patient did not react to a previous Xolair injection. Anaphylaxis can occur up to 24 hours after the injection is given.

Around the region  -  Mar 9, 2007
Houston Chronicle,Tanox makes the injectable asthma medicine Xolair, which Genentech co-markets with Novartis. Antitrust regulators requested more information on the purchase

Most Patients With Moderate to Severe Asthma Have Suboptimal ...  -  Mar 1, 2007
DG NewsREACT is funded by Genentech, Inc., which manufactures omalizumab (Xolair). [Presentation title: Real-World Evaluation of Asthma Control and Treatment

Adverse patent ruling could cost Genentech millions  -  Feb 28, 2007
San Diego Daily Transcript (subscription),...the asthma medication Xolair because some patients taking the drug had suffered life-threatening reactions that inhibits breathing known as anaphylaxis.

Genentech on a roll  -  Feb 25, 2007
Miami Herald,Last quarter it bought Tanox, its partner for the asthma treatment Xolair. Unfortunately, Genentech's shares are pricey, at 44 times last year's earnings

Pharma Sector: Few Newsmakers Of The Week - Basilea Glaxo ...  -  25 Feb 2007
Trading Markets,Genentech's asthma drug Xolair, which had to trudge a bumpy road before being approved in June 2003, is now hit with another snag. Xolair - administered as

Mayo Clinic info now on cell phones  -  25 Feb 2007
Chicago Sun-Times,The federal Food and Drug Administration is warning that the asthma drug Xolair can cause a life-threatening allergic reaction.

FDA Issues New Warning About Asthma Drug Xolair  -  Feb 22, 2007
Newsinferno.com,Xolair was approved by the FDA in 2003 to treat patients with allergy-related asthma. It was previously believed that the risk of anaphylaxis was most

FDA Proposes to Strengthen Label Warning for Xolair  -  Feb 22, 2007
eMaxHealth.com,The boxed warning emphasizes that Xolair, used to treat patients with asthma related to allergies, may cause anaphylaxis. Anaphylaxis may include trouble

Proposed Boxed Warning for Xolair  -  Feb 22, 2007
Facts and Comparisons,Reactions may occur after any Xolair dose, even in patients experiencing none to the first dose. Health care professionals should monitor Xolair-treated

FDA wants stronger warning on Genentech's Xolair  -  Feb 22, 2007
Pharma Times (subscription),The US Food and Drug Administration says that Genentech's asthma treatment Xolair should carry a stronger label warning after the agency received new

FDA Warns on Asthma Drug Xolair  -  Feb 22, 2007
Smartmoney.comThe agency said it's asked the company to put a black-box warning label on the drug, which is sold under the brand name Xolair. A black box warning is the

FDA Mandates Stronger Warning on Asthma Drug Xolair  -  Feb 22, 2007
HealthCentral.com,The new alert for Xolair (omalizumab), marketed by Genentech Inc., draws attention to anaphylaxis as a potential side effect of the medication.

Xolair Linked to Risk for Delayed-Onset Anaphylaxis  -  Feb 22, 2007
Medscape (subscription)February 22, 2007 — Omalizumab subcutaneous injection (Xolair, made by Genentech, Inc) may be linked to life-threatening anaphylaxis, according to a warning

FDA proposes to strengthen label warning for Xolair  -  Feb 21, 2007
People's Daily Online,The boxed warning emphasizes that Xolair, used to treat patients with asthma related to allergies, may cause anaphylaxis. The cases were reported at a

FDA Warns About Asthma Drug, Xolair  -  Feb 21, 2007
WebMD21, 2007 -- The FDA is calling for a "black box" label warning for the asthmaasthma drug Xolair, alerting users it can cause potentially life-threatening

FDA MedWatch: Xolair (omalizumab) New Reports of Serious and Life ...  -  Feb 21, 2007
PharmaLive.com (press release),Usually these reactions occur within two hours of receiving a Xolair subcutaneous injection. However, these new reports include patients who had delayed

FDA Orders Strengthened Warning for Biologic Asthma Drug Xolair  -  Feb 21, 2007
Biologic Drug Report,21st announced that it had ordered Genentech to add a stronger warning to the label for injected biologic drug Xolair (omalizumab) emphasizing that the drug

Asthma Drug Xolair Gets New Warnings  -  Feb 21, 2007
NBC5.com,The risk of anaphylaxis was known when Xolair, also called omalizumab, was approved as an asthma treatment in 2003. But the Food and Drug Administration

FDA orders warnings for Xolair  -  Feb 21, 2007
Therapeutics Daily (subscription) (press release),The US Food and Drug Administration ordered Genentech Inc. to add a boxed warning to its asthmatic drug marketed as Xolair.

FDA Orders Stronger Warnings For Xolair  -  Feb 21, 2007
CBS News,Anaphylaxis can occur even if a patient did not react to a previous Xolair injection. Anaphylaxis can occur up to 24 hours after the injection is given.

FDA asks for warning on Genentech drug Xolair  -  Feb 21, 2007
San Francisco Business Times,The Food and Drug Administration said Wednesday that it wants Genentech Inc. to put a boxed warning on the label of the asthma drug Xolair.

FDA orders warnings for Xolair  -  Feb 21, 2007
DailyIndia.com,21 (UPI) -- The US Food and Drug Administration ordered Genentech Inc. to add a boxed warning to its asthmatic drug marketed as Xolair.

FDA orders warnings for Xolair  -  Feb 21, 2007
ImediNews,WASHINGTON (UPI) — The US Food and Drug Administration ordered Genentech Inc. to add a boxed warning to its asthmatic drug marketed as Xolair.

FDA orders warnings for Xolair  -  Feb 21, 2007
Earthtimes.org21 The US Food and Drug Administration ordered Genentech Inc. to add a boxed warning to its asthmatic drug marketed as Xolair.

FDA Calls For Tough Warning on Genentech's Xolair Asthma Drug  -  Feb 21, 2007
CNBC,...[DNA 87.04 0.10 (+0.12%) ] asthma drug Xolair should carry the strongest warning possible about the drug's risk of a serious reaction known as anaphylaxis,

FDA Orders Black Box Anaphylaxis Warning for Omalizumab (Xolair)  -  Feb 21, 2007
MedPage Today,21 -- Anaphylaxis reports associated with the asthma drug omalizumab (Xolair) led the FDA today to order Genentech to add a black box warning to the agent's

PTO to Genentech: Cabilly is Silly  -  Feb 22, 2007
The Deal Blogs,Second, the FDA warned the company's asthma drug, Xolair, should have the strongest possible warning for anaphylaxis, a severe allergic reaction that occurs

Genentech loses ruling on patent that brings in millions annually  -  Feb 22, 2007
Contra Costa Times,Separately, US regulators Wednesday told Genentech, based in South San Francisco, to stiffen a warning that the asthma drug Xolair may cause

Strong warnings ordered for injected asthma drug  -  Feb 23, 2007
Columbus Dispatch,The risk of anaphylaxis was known when Xolair was approved as an asthma treatment in 2003. But the Food and Drug Administration ordered the drug

Genentech loses patent ruling  -  Feb 22, 2007
Tri-Valley Herald,Also, in other news, South San Francisco-based Genentech announced that US regulators told the company to stiffen a warning that its asthma drug Xolair may

FDA Warns About Genentech Drug  -  Feb 21, 2007
Wall Street Journal (subscription),The agency said it has asked Genentech to put a so-called black-box warning label on the drug, which is sold under the brand name Xolair.

Patent ruling could cost Genentech $100 million  -  Feb 22, 2007
San Francisco Chronicle,Separately Wednesday, the Food and Drug Administration asked Genentech to strengthen warnings on the label for its asthma drug Xolair to reflect a possibly

FDA Orders Stronger Asthma Drug Warning  -  Feb 21, 2007
Business Portal 24 (press release),The risk of anaphylaxis was known when Xolair, also called omalizumab, was approved as an asthma treatment in 2003. But the Food and Drug

Allergic Reaction, FDA Says  -  Feb 21, 2007
Wall Street Journal (subscription),WASHINGTON -- The Food and Drug Administration warned that Genentech Inc.'s asthma drug Xolair can cause a life-threatening allergic reaction and asked the

US orders warnings on ADHD drug labels  -  Feb 21, 2007
Louisville Courier-Journal,The FDA ordered stronger label warnings for an injected asthma medication because of reports some patients taking the drug, marketed as Xolair,

Asthma wonder jab could kill, warn the Americans  -  Feb 22, 2007
Daily Mail,The move comes after some users developed a delayed and potentially life-threatening reaction to Xolair, which was licensed in the UK in 2005.

Asthma drug to get stronger label warnings  -  Feb 22, 2007
Wilmington Morning Star,Anaphylaxis can occur even if a patient did not react to a previous Xolair injection. Anaphylaxis can occur up to 24 hours after the injection.

FDA orders warning 'guides' for ADHD drugs  -  Feb 21, 2007
USA Today...•The FDA has asked Genentech to add a black-box warning — the strongest type — to the label of Xolair, which is used to treat patients with asthma related

FDA seeks tough warning on Genentech asthma drug  -  Feb 21, 2007
Scientific AmericanWASHINGTON (Reuters) - Genentech Inc's asthma drug Xolair should carry the strongest warning possible about the drug's risk of a serious reaction known as

UPDATE 2-US seeks tough warning on Genentech asthma drug  -  Feb 21, 2007
ReutersN: Quote, Profile , Research) asthma drug Xolair should carry the strongest warning possible about a potentially deadly reaction known as anaphylaxis,

Injected Asthma Drug To Carry New Warnings  -  Feb 21, 2007
KOLD-TV,Doctors are being told to observe patients for at least two hours after they get the Xolair injection. The warning says anaphylaxis can occur even if a

Tanox Shareholders Approve Genentech Acquisition  -  18 Jan 2007
CBS 5,In addition, Genentech will now receive Xolair royalty payments from Novartis, which owns sales rights outside the country.

RPT Novartis pharma chief sees record number of product launches ...  -  18 Jan 2007
Euro2day,...several key product roll-outs to take place over the course of next year, such as asthma drug Xolair, and Exjade which counters high iron content.

Novartis Strategic Healthcare Portfolio Drives Sustained Strong ...  -  18 Jan 2007
PharmaLive.com (press release),New product launches, particularly Xolair, Exjade and Prexige, supported the performance. US net sales were up 17%, outpacing the market.

Stocks Poised to Extend Rally  -  Jan 16, 2007
Smartmoney.comTanox developed the asthma treatment Xolair, which is already marketed by Genentech domestically. Xolair will continue to be marketed by Novartis (NVS)

Asthmatics to be denied life-changing drug twice  -  Jan 13, 2007
Sunday Herald,The drug, called Xolair, is designed for those with severe, persistent asthma that cannot be controlled by standard treatments. Clinical trials have shown

Tanox Shareholders OK Acquisition  -  Jan 15, 2007
CBS News,In addition, Genentech will now receive Xolair royalty payments from Novartis, which owns sales rights outside the country.

Tanox, Inc. Stockholders Approve Merger With Genentech, Inc.  -  Jan 15, 2007
PharmaLive.com (press release),Xolair was developed in collaboration with Genentech, Inc. and Novartis Pharma AG and is approved for marketing in the United States, Canada and major

Tanox shareholders approve acquisition by Genentech  -  Jan 15, 2007
International Herald Tribune,...partnership Genentech and Tanox share with Novartis AG in the development and commercialization of the asthma-fighting drug Xolair, which Tanox created.

Tanox shareholders OK acquisition  -  Jan 15, 2007
Ely Times,...partnership Genentech and Tanox share with Novartis AG in the development and commercialization of the asthma-fighting drug Xolair, which Tanox created.

Tanox shareholders approve acquisition by Genentech  -  Jan 15, 2007
KESQ,Genentech and Tanox share with Novartis AG. They deal involves development and commercialization of an asthma-fighting drug (Xolair), which Tanox created.

Tanox shareholders OK Genentech buyout  -  Jan 15, 2007
East Bay Business Times,The two companies have been working together with Novartis on the asthma treatment Xolair. The transaction is expected to close in the first quarter of 2007

Tanox shareholders approve Genentech deal  -  Jan 15, 2007
Sacramento Business Journal,The two firms have been working together with Novartis on the asthma treatment Xolair. The transaction is expected to close in the first quarter of 2007.

Funding for asthma drug rejected  -  Jan 15, 2007
ic WestLothian.co.uk,The Scottish Medicines Consortium (SMC) again chose not to approve Xolair for use by NHS Scotland. Medical chiefs originally knocked it back in June last

Genentech puts muscle behind blood drug  -  Jan 10, 2007
DrugResearcher.com,Genentech and Tanox had been working in collaboration with Novartis for 10 years to develop and commercialise Xolair (omalizumab), an anti-IgE monoclonal

Genentech on A Roll  -  Jan 12, 2007
MSNBCIt made an acquisition last quarter when it bought Tanox (Nasdaq: TNOX), its partner for the asthma treatment, Xolair. Genentech also signed another drug

Strong Lucentis sales help Genentech earnings soar  -  Jan 11, 2007
Pharma Times (subscription),As for Genentech's other key products, arthritis and non-Hodgkin's lymphoma drug Rituxan (rituximab) posted a 16% gain to $560 million, while Xolair

TECH TICKER  -  Jan 16, 2007
San Jose Mercury News,The purchase will eliminate royalties that Genentech has been paying for Xolair, an injectable drug for moderate to severe asthma that it co-markets with

Compiled from wire reports  -  Jan 16, 2007
Newsday,The purchase will eliminate royalties that Genentech, based in South San Francisco, has been paying for Xolair, an injectable drug for moderate-to-severe

Genentech Q4 2006 Earnings Call Transcript  -  Jan 10, 2007
Seeking Alpha,Next to our other immunology products, US sales for Xolair were $117 million in Q4 and $425 million in 2006, a 33% increase compared to the full year of

Drugmakers' `Arms Race' May Spur Biotechnology Deals (Update2)  -  Jan 12, 2007
Bloomberg2 biotechnology company, agreed to buy its partner Tanox Inc. in November, gaining the asthma medication Xolair. The $919 million transaction was the first

Six Flags planning to sell Waterworld  -  Jan 12, 2007
Contra Costa Times,Houston-based Tanox makes the injectable asthma drug Xolair, which Genentech co-markets with the Swiss pharmaceutical company Novartis AG.

Genentech Announces Full Year and Fourth Quarter 2006 Results  -  Jan 10, 2007
PR Newswire (press release),Herceptin(R) 322 250 29 1234 747 65 Tarceva(R) 107 84 27 402 275 46 Nutropin(R) products 101 95 6 378 370 2 Xolair(R) 117 93 26 425 320 33 Thrombolytics

Earnings Preview: Genentech  -  Jan 9, 2007
Houston Chronicle,Also in November, Genentech said it would buy Tanox Inc., its partner on the asthma drug Xolair, for $919 million. That gave Genentech potential drug

Earnings Preview: Genentech  -  Jan 9, 2007
Forbes,Also in November, Genentech said it would buy Tanox Inc. (nasdaq: TNOX - news - people ), its partner on the asthma drug Xolair, for $919 million.

Biotech firm gets rights to drug  -  Dec 21, 2006
San Francisco Chronicle,Genentech said in November that it would buy its partner Tanox Inc. to gain full US rights to the Xolair asthma drug that the companies developed and sell

Improved Quarter for Biotech on Capital Markets ... and Financings ...  -  Jan 2, 2007
PR Newswire (press release),The companies have been working together in collaboration with Novartis since 1996 to develop and commercialize Xolair(R), an anti-IgE monoclonal antibody

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional